Castle Biosciences (CSTL) Earnings Date, Estimates & Call Transcripts $30.05 -0.48 (-1.57%) (As of 09:02 AM ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Earnings SummaryUpcoming Earnings DateNov. 7EstimatedActual EPS (Aug. 5) $0.31 Beat By $0.47 Consensus EPS (Aug. 5) -$0.16 Conference Call TranscriptConference Call AudioEarnings Press ReleaseEarnings Slide Deck Get Castle Biosciences Earnings AlertsEnter your email address below to receive the latest news and earnings results for CSTL and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueCSTL Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.CSTL Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Stansberry ResearchNew President Kamala warningFinancial nightmare coming after election In 2018, one independent research predicted Kamala Harris was on her way to becoming the president of the United States. "Frankly, she scares us to death… and she should scare you," they wrote.Which is why you need to check out their newest Kamala prediction immediately. Castle Biosciences Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany GuidanceQ1 20242($0.71)($0.37)($0.54) Q2 20242($0.63)($0.16)($0.40) Q3 20242($0.53)($0.08)($0.31) Q4 20242($0.80)($0.42)($0.61) FY 20248($2.67)($1.03)($1.85) Q1 20251($0.63)($0.63)($0.63) Q2 20251($0.47)($0.47)($0.47) Q3 20251($0.46)($0.46)($0.46) Q4 20251($0.39)($0.39)($0.39) FY 20254($1.95)($1.95) ($1.95)CSTL Earnings Date and InformationCastle Biosciences last released its quarterly earnings results on August 5th, 2024. The reported $0.31 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.47. The business had revenue of $87 million for the quarter, compared to analysts' expectations of $69.95 million. Castle Biosciences has generated ($1.15) earnings per share over the last year (($1.15) diluted earnings per share). Earnings for Castle Biosciences are expected to decrease in the coming year, from ($0.58) to ($2.13) per share. Castle Biosciences has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 7th, 2024 based off prior year's report dates.Read More Castle Biosciences Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks 11/7/2024(Estimated)------- 8/5/2024Q2 2024($0.16)$0.31+$0.47$0.31$69.95 million$87.00 million 5/2/2024Q1 2024($0.37)($0.09)+$0.28($0.09)$68.34 million$72.97 million 2/28/2024Q4 2023($0.84)($0.10)+$0.74($0.10)$51.32 million$66.12 million 11/2/2023Q3 2023($0.92)($0.26)+$0.66($0.26)$44.94 million$61.49 million 8/2/2023Q2 2023($1.01)($0.70)+$0.31($0.70)$43.51 million$50.14 million 5/3/2023Q1 2023($0.80)($1.10)($0.30)($1.10)$37.63 million$42.04 million Get the Latest News and Ratings for CSTL and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Castle Biosciences and its competitors with MarketBeat's FREE daily newsletter. 2/28/2023Q4 2022($0.91)($0.78)+$0.13($0.78)$36.53 million$38.34 million 11/2/2022Q3 2022($0.70)($0.77)($0.07)($0.77)$34.36 million$37.01 million 8/8/2022Q2 2022($0.58)($0.06)+$0.52($0.06)$28.40 million$34.84 million 5/9/2022Q1 2022($0.67)($0.80)($0.13)($0.63)$25.13 million$26.85 million 2/28/2022Q4 2021($0.43)($0.25)+$0.18($0.25)$23.43 million$25.04 million 11/7/2021Q3 2021($0.34)($0.47)($0.13)($0.47)$23.66 million$23.48 million 8/8/2021Q2 2021($0.29)($0.34)($0.05)($0.33)$19.09 million$22.76 million 5/9/2021Q1 2021($0.23)($0.17)+$0.06($0.17)$16.66 million$22.81 million 3/7/2021Q4 2020($0.11)($0.23)($0.12)($0.09)$15.74 million$17.30 million 11/14/2020Q3 2020($0.11)($0.23)($0.12)($0.23)$15.31 million$15.22 million 8/10/2020Q2 2020($0.41)($0.08)+$0.33($0.08)$9.15 million$12.72 million 5/11/2020Q1 2020($0.15)$0.03+$0.18$0.03$14.40 million$17.42 million 3/10/2020Q4 2019($0.20)$0.11+$0.31$0.11$12.66 million$17.64 million 11/11/2019Q3($0.31)$0.02+$0.33($0.67)$10.28 million$14.78 million Castle Biosciences Earnings - Frequently Asked Questions When is Castle Biosciences's earnings date? Castle Biosciences has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 7th, 2024 based off last year's report dates. Learn more on CSTL's earnings history. What guidance has Castle Biosciences issued on next quarter's earnings? Castle Biosciences updated its FY 2024 earnings guidance on Monday, August, 5th. The company issued revenue guidance of $275.0 million-$300.0 million, compared to the consensus revenue estimate of $260.4 million. Did Castle Biosciences beat their earnings estimates last quarter? In the previous quarter, Castle Biosciences (NASDAQ:CSTL) reported $0.31 earnings per share (EPS) to beat the analysts' consensus estimate of ($0.16) by $0.47. Learn more on analysts' earnings estimate vs. CSTL's actual earnings. How can I listen to Castle Biosciences's earnings conference call? The conference call for Castle Biosciences's latest earnings report can be listened to online. Listen to Conference Call How can I read Castle Biosciences's conference call transcript? The conference call transcript for Castle Biosciences's latest earnings report can be read online. Read Transcript How much revenue does Castle Biosciences generate each year? Castle Biosciences (NASDAQ:CSTL) has a recorded annual revenue of $287.59 million. How much profit does Castle Biosciences generate each year? Castle Biosciences (NASDAQ:CSTL) has a recorded net income of -$57.47 million. CSTL has generated -$1.15 earnings per share over the last four quarters. What is Castle Biosciences's EPS forecast for next year? Castle Biosciences's earnings are expected to decrease from ($0.58) per share to ($2.13) per share in the next year. More Earnings Resources from MarketBeat Related Companies: RNLX Earnings MYGN Earnings GH Earnings HIMS Earnings CON Earnings ARDT Earnings LFST Earnings BTSG Earnings ADUS Earnings VCYT Earnings Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: GameStop: Earnings Won’t Save It, Dilution Points to TroubleIs Merck Stock Undervalued After Its Colossal Earnings Growth?Polestar Lives to Fight Another Day After Q2 EarningsWhy NVIDIA’s Earnings Point to a Bullish Future for Pure StorageDoes A&F's Q2 Earnings Win Point to a Strong Holiday Season?Salesforce Beats Earnings, Raises Full-Year Profit OutlookDon’t Count Out CrowdStrike Yet: Key Insights from Q2 Earnings This page (NASDAQ:CSTL) was last updated on 9/20/2024 by MarketBeat.com Staff From Our PartnersBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredNew President Kamala warningFinancial nightmare coming after election In 2018, one independent research predicted Kamala Harris was on ...Stansberry Research | SponsoredBiden's Executive Order, Dems Digital Money Legislation, First Step ToDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans...Monetary Gold | SponsoredAct by Friday, August 16th, to collect this 22% dividendLet's do a little math here... To double your money at a 3% rate of return, you would need around 23 years....Investors Alley | SponsoredThis Crypto Is Set to Explode in SeptemberWith thousands of cryptocurrencies out there, it's crucial to focus on the ONE that has the potential to make ...Crypto 101 Media | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredNew September Stock WarningSeptember is the most volatile month of the year for stocks. And after the brutal tech selloff, one Wall St...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Castle Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Castle Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
